Literature DB >> 8836976

Altered energy metabolism in Alzheimer's disease.

M Ogawa1, H Fukuyama, Y Ouchi, H Yamauchi, J Kimura.   

Abstract

To evaluate the energy metabolism in Alzheimer's disease (AD), the cerebral arteriovenous differences of oxygen, glucose, lactate, pyruvate, ketone bodies and free fatty acids, and regional cerebral blood flow (rCBF) were examined in 7 patients with Alzheimer's disease (AD). The ratio of oxygen and glucose molar utilization was significantly elevated to 9.86 in AD, compared with 5.63 for 7 age matched controls. Single-photon emission computed tomography revealed that the patients had significantly decreased rCBF only in the parietotemporal region. The glucose extraction fraction and global cerebral metabolic rate of glucose were significantly decreased, whereas the global cerebral metabolic rate of oxygen was slightly decreased. However, the elevated oxygen/glucose utilization ratio is not due to the oxygenation of ketone bodies or free fatty acids, because the cerebral metabolic rates of these substrates did not alter. We concluded that the marked elevated value of the oxygen/glucose utilization ratio suggests an altered energy metabolism in AD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8836976

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  19 in total

Review 1.  Redox proteomics in some age-related neurodegenerative disorders or models thereof.

Authors:  D Allan Butterfield; Hafiz Mohmmad Abdul; Shelley Newman; Tanea Reed
Journal:  NeuroRx       Date:  2006-07

2.  The Antiepileptic Ketogenic Diet Alters Hippocampal Transporter Levels and Reduces Adiposity in Aged Rats.

Authors:  Abbi R Hernandez; Caesar M Hernandez; Keila T Campos; Leah M Truckenbrod; Yasemin Sakarya; Joseph A McQuail; Christy S Carter; Jennifer L Bizon; Andrew P Maurer; Sara N Burke
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2018-03-14       Impact factor: 6.053

3.  Test-retest reproducibility of a rapid method to measure brain oxygen metabolism.

Authors:  Peiying Liu; Feng Xu; Hanzhang Lu
Journal:  Magn Reson Med       Date:  2012-04-19       Impact factor: 4.668

Review 4.  Potential for Ketotherapies as Amyloid-Regulating Treatment in Individuals at Risk for Alzheimer's Disease.

Authors:  Matthew K Taylor; Debra K Sullivan; Jessica E Keller; Jeffrey M Burns; Russell H Swerdlow
Journal:  Front Neurosci       Date:  2022-06-16       Impact factor: 5.152

Review 5.  Intracerebroventricular Streptozotocin Injections as a Model of Alzheimer's Disease: in Search of a Relevant Mechanism.

Authors:  Paweł Grieb
Journal:  Mol Neurobiol       Date:  2015-03-07       Impact factor: 5.590

6.  Emulsification Increases the Acute Ketogenic Effect and Bioavailability of Medium-Chain Triglycerides in Humans: Protein, Carbohydrate, and Fat Metabolism.

Authors:  Alexandre Courchesne-Loyer; Carolyn-Mary Lowry; Valérie St-Pierre; Camille Vandenberghe; Mélanie Fortier; Christian-Alexandre Castellano; J Richard Wagner; Stephen C Cunnane
Journal:  Curr Dev Nutr       Date:  2017-06-21

7.  Can nutrition support healthy cognitive ageing and reduce dementia risk?

Authors:  Amy Jennings; Stephen C Cunnane; Anne Marie Minihane
Journal:  BMJ       Date:  2020-06-26

Review 8.  Dietary Neuroketotherapeutics for Alzheimer's Disease: An Evidence Update and the Potential Role for Diet Quality.

Authors:  Matthew K Taylor; Russell H Swerdlow; Debra K Sullivan
Journal:  Nutrients       Date:  2019-08-15       Impact factor: 5.717

9.  Strategies for molecular imaging dementia and neurodegenerative diseases.

Authors:  Bernhard J Schaller
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570

10.  Can Ketones Help Rescue Brain Fuel Supply in Later Life? Implications for Cognitive Health during Aging and the Treatment of Alzheimer's Disease.

Authors:  Stephen C Cunnane; Alexandre Courchesne-Loyer; Camille Vandenberghe; Valérie St-Pierre; Mélanie Fortier; Marie Hennebelle; Etienne Croteau; Christian Bocti; Tamas Fulop; Christian-Alexandre Castellano
Journal:  Front Mol Neurosci       Date:  2016-07-08       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.